Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

Although the field of pharmacogenetics has existed for decades, practioners have been slow to implement pharmacogenetic testing in clinical care. Numerous publications describe the barriers to clinical implementation of pharmacogenetics. Recently, several freely available resources have been developed to help address these barriers. In this review, we discuss current programs that use preemptive genotyping to optimize the pharmacotherapy of patients. Array-based preemptive testing includes a large number of relevant pharmacogenes that impact multiple high-risk drugs. Using a preemptive approach allows genotyping results to be available prior to any prescribing decision so that genomic variation may be considered as an inherent patient characteristic in the planning of therapy. This review describes the common elements among programs that have implemented preemptive genotyping and highlights key processes for implementation, including clinical decision support.

[1]  Urs A. Meyer,et al.  Pharmacogenetics – five decades of therapeutic lessons from genetic diversity , 2004, Nature Reviews Genetics.

[2]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte , 2008, Clinical pharmacology and therapeutics.

[3]  M. Relling,et al.  Development and implementation of a pharmacist-managed clinical pharmacogenetics service. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[4]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy , 2011, Clinical pharmacology and therapeutics.

[5]  Nicole A. Restrepo,et al.  Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. , 2013, Pharmacogenomics.

[6]  R. Verbrugge,et al.  Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey , 2012, Clinical pharmacology and therapeutics.

[7]  J. Kelsoe,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Carbamazepine Dosing , 2012, Clinical pharmacology and therapeutics.

[8]  Christopher G Chute,et al.  Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. , 2014, Mayo Clinic proceedings.

[9]  A L Fuhlbrigge,et al.  Economic Evaluation of Pharmacogenetic Tests , 2008, Clinical pharmacology and therapeutics.

[10]  George Hripcsak,et al.  Opportunities for genomic clinical decision support interventions , 2013, Genetics in Medicine.

[11]  Julie A Johnson,et al.  Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. , 2013, Pharmacogenomics.

[12]  J J Swen,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapeutics.

[13]  Monique W. M. Jaspers,et al.  Effects of clinical decision-support systems on practitioner performance and patient outcomes: a synthesis of high-quality systematic review findings , 2011, J. Am. Medical Informatics Assoc..

[14]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update , 2014, Clinical pharmacology and therapy.

[15]  M. Relling,et al.  Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods , 2012, Clinical pharmacology and therapeutics.

[16]  L. Gong,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens , 2014, Clinical pharmacology and therapy.

[17]  Russ B Altman,et al.  PharmGKB: the Pharmacogenomics Knowledge Base. , 2013, Methods in molecular biology.

[18]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.

[19]  F. Collins,et al.  The path to personalized medicine. , 2010, The New England journal of medicine.

[20]  L Gong,et al.  The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy , 2012, Clinical pharmacology and therapeutics.

[21]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.

[22]  N. Reynolds,et al.  British Association of Dermatologists’ guidelines for the safe and effective prescribing of azathioprine 2011 , 2011, The British journal of dermatology.

[23]  Ching-Hon Pui,et al.  PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[24]  R. Altman,et al.  Implementing Personalized Medicine: Development of a Cost‐Effective Customized Pharmacogenetics Genotyping Array , 2012, Clinical pharmacology and therapeutics.

[25]  E. Clayton,et al.  Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project , 2012, Clinical pharmacology and therapeutics.

[26]  Joshua P Cohen,et al.  Clinical and economic challenges facing pharmacogenomics , 2012, The Pharmacogenomics Journal.

[27]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[28]  C. Lerman,et al.  Anticipating Clinical Integration of Pharmacogenetic Treatment Strategies for Addiction: Are Primary Care Physicians Ready? , 2008, Clinical pharmacology and therapeutics.

[29]  Kristin A. Maloney,et al.  The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation , 2013, Clinical pharmacology and therapeutics.

[30]  R. Altman,et al.  Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. , 2010, The Lancet. Oncology.

[31]  M. Relling,et al.  Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.

[32]  R. Weinshilboum,et al.  The Impact of Pharmacogenomics on the Management of Cardiac Disease , 2011, Clinical pharmacology and therapeutics.

[33]  M. Relling,et al.  Thiopurine methyltransferase in acute lymphoblastic leukemia. , 2006, Blood.

[34]  S. Scott,et al.  Personalizing medicine with clinical pharmacogenetics , 2011, Genetics in Medicine.

[35]  G. Ginsburg,et al.  Institutional Profile: A hub for bench-to-bedside pharmacogenomic-based research , 2011 .

[36]  Eun-Young Kim,et al.  Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement , 2009, Pharmacogenetics and genomics.

[37]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[38]  S. Teutsch,et al.  Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? , 2009, Genetics in Medicine.

[39]  Brandon M. Welch,et al.  The Need for Clinical Decision Support Integrated with the Electronic Health Record for the Clinical Application of Whole Genome Sequencing Information , 2013, Journal of Personalized Medicine.

[40]  R. Altman,et al.  Personal Genomic Measurements: The Opportunity for Information Integration , 2013, Clinical pharmacology and therapeutics.

[41]  Melissa A. Basford,et al.  Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping , 2012, Clinical pharmacology and therapeutics.

[42]  C. Pui,et al.  Pharmacogenomics and Individualized Medicine: Translating Science Into Practice , 2012, Clinical pharmacology and therapeutics.

[43]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.

[44]  R. Weinshilboum,et al.  Challenges in Implementing Genomic Medicine: The Mayo Clinic Center for Individualized Medicine , 2013, Clinical pharmacology and therapeutics.

[45]  Teri E. Klein,et al.  Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process , 2014, Current drug metabolism.

[46]  M. Manns,et al.  Diagnosis and management of autoimmune hepatitis , 2010, Hepatology.

[47]  Nora Husain,et al.  The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency , 2012, Nucleic Acids Res..

[48]  Shih-Chieh Chang,et al.  Images in clinical medicine. Acute mesenteric infarction associated with atrial fibrillation. , 2011, The New England journal of medicine.

[49]  Hoangmai H Pham,et al.  Care patterns in Medicare and their implications for pay for performance. , 2007, The New England journal of medicine.

[50]  L. Garrison,et al.  A Formal Risk-benefit Framework for Genomic Tests: Facilitating the Appropriate Translation of Genomics into Clinical Practice , 2022 .

[51]  Erica A. Bowton,et al.  Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing , 2013, Clinical pharmacology and therapeutics.

[52]  M. Guyer,et al.  Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.

[53]  D. Roden,et al.  The Emerging Role of Electronic Medical Records in Pharmacogenomics , 2011, Clinical pharmacology and therapeutics.

[54]  C. Thorn,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen‐B Genotype and Allopurinol Dosing , 2013, Clinical pharmacology and therapeutics.

[55]  M R Wilkinson,et al.  A Clinician‐Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record , 2012, Clinical pharmacology and therapeutics.

[56]  M. Relling,et al.  Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia , 2009, Clinical pharmacology and therapeutics.

[57]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[58]  Julie A. Johnson,et al.  Pharmacogenetics in clinical practice: how far have we come and where are we going? , 2013, Pharmacogenomics.

[59]  Jeffrey C. Hall,et al.  The CLIPMERGE PGx Program: Clinical Implementation of Personalized Medicine Through Electronic Health Records and Genomics–Pharmacogenomics , 2013, Clinical pharmacology and therapeutics.

[60]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[61]  J. Mega,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[62]  M. Relling,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype , 2014, Clinical pharmacology and therapeutics.

[63]  N J Cox,et al.  The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics , 2012, Clinical pharmacology and therapeutics.

[64]  R L Berg,et al.  Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing , 2010, Clinical pharmacology and therapeutics.

[65]  Teri E. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing , 2013, Clinical pharmacology and therapeutics.

[66]  E. Green,et al.  Genomics Reaches the Clinic: From Basic Discoveries to Clinical Impact , 2011, Cell.

[67]  Richard M Weinshilboum,et al.  Genomics and drug response. , 2011, The New England journal of medicine.

[68]  M. Rudis,et al.  Assessment of the Pharmacogenomics Educational Needs of Pharmacists , 2011, American Journal of Pharmaceutical Education.

[69]  Russ B Altman,et al.  PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. , 2005, Methods in molecular biology.

[70]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.

[71]  R B Altman,et al.  Challenges in the Pharmacogenomic Annotation of Whole Genomes , 2013, Clinical pharmacology and therapeutics.

[72]  Jon W. McKeeby,et al.  Integrating pharmacogenetic information and clinical decision support into the electronic health record , 2014, J. Am. Medical Informatics Assoc..